COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission.

OBJECTIVE: As the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols. RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses. CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged groups.

Evaluation of serum HGF and CK18 levels in patients with esophageal cancer.

Cytokeratins are thought to play a role in apoptosis. Cytokeratin 18 (CK18) is involved in the formation of intracellular cytoskeleton, and has been considered a promising apoptosis marker in gastrointestinal carcinomas. Growth factors, including hepatocyte growth factor (HGF), may provide a microenvironment for malignant cells. In this study, we aimed to compare serum HGF and CK18 levels between esophageal squamous cell carcinoma patients and healthy controls. The study included 41 adult patients (20 male, 21 female) diagnosed with esophageal squamous cell carcinoma, with a mean age of 63.54 ± 10.88 years (range, 41-82 years). We also recruited 39 age and gender-matched healthy control subjects. Venous blood samples were taken; serum HGF and CK18 concentrations were determined via ELISA. Results indicated that serum HGF levels were higher in patients (1.37 ± 0.63 ng/mL) as compared to the healthy subjects (0.41 ± 0.29 ng/mL). Similarly, serum CK18 levels were higher in the patient group (2.53 ± 1.33 ng/mL) than in the control group (0.34 ± 0.23 ng/mL) (P < 0.001). In addition, serum HGF and CK18 levels were positively correlated with metastasis stage, tumor stage, and disease stage of esophageal squamous cell carcinoma. To our knowledge, this is the first study to evaluate serum HGF and CK18 levels in patients with esophageal squamous cell carcinoma. The results suggest that serum CK18 and HGF levels may be used as prognostic and disease monitoring biomarkers of esophageal squamous cell carcinoma.

Plasma homocysteine and liver tissue S-adenosylmethionine, S-adenosylhomocysteine status in vitamin B6-deficient rats.

OBJECTIVE: The aim of this study was to evaluate plasma homocysteine (Hcy), malondialdehyde (MDA), glutathione (GSH) levels, glutathione peroxidase (GSH-Px) and glutathione-S-transferase (GST) activities and liver tissue S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels in control and vitamin B6-deficient rats. MATERIALS AND METHODS: Thirty-two male rats with a weight of 65-75 g were used for the experiment. The rats were divided into control (n=16) and vitamin B6-deficient groups. At the end of the experiment, the animals were anesthetized with ketamine-HCl (Ketalar, 20 mg/kg, i.p.), and the blood was collected by cardiac puncture after thoracotomy. Plasma Hcy, pyridoxal phosphate (PLP), liver SAM, SAH levels measured by an isocratic system with high performance liquid chromatography. Plasma GSH-Px, GSH activities and GSH, MDA levels were carried out using a spectrophotometer. RESULTS: Plasma Hcy, MDA, liver tissue SAH levels were significantly increased, whereas plasma GSH, PLP, liver tissue SAM levels, plasma GST, GSH-Px activities and SAM/SAH ratio were decreased compared to those of control group. CONCLUSIONS: Vitamin B6 deficiency causes an increase in plasma homocysteine levels. Thus, we think that vitamin B6 supplementation could be used for therapeutic purposes in hyperhomocysteinemia condition.

The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: a prospective, randomised, placebo-controlled study.

The purpose was to determine the effects of oral zinc sulphate along with radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer. Thirty patients with head and neck cancer were randomly assigned to receive either zinc sulphate capsules (including 50 mg zinc) (n = 15) or placebo (n = 15) three times a day, starting on the day of the first radiotherapy fraction and continuing throughout the scheduled radiotherapy course including weekends and 6 weeks after radiotherapy. The patients were treated with telecobalt radiation at conventional fractionation of 2 Gy/fraction and five fractions/ week in 20-35 fractions for a period of 4-7 weeks. Blood samples for biochemical parameters were collected after an overnight fast (12 h) before radiotherapy, the first day and 6 weeks after radiotherapy. In the placebo group, three patients were excluded. No difference was detected in any final measurement activities of erythrocyte anti-oxidant enzyme such as copper-zinc superoxide dismutase (Cu-Zn SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in the direct comparison between the zinc sulphate and the placebo group, except erythrocyte SOD activities measured the first day after radiotherapy (p < 0.03). In the respective measurement analysis of the groups in themselves, in the zinc sulphate group, while the statistical analysis for the activities of erythrocyte CAT and GSH-Px were significantly different (chi2 = 12.4, p < 0.05; chi2 = 8.9, p < 0.05, respectively) before radiotherapy, the first day and 6 weeks after radiotherapy, the activities of SOD did not differ (chi2 = 4.2, p > 0.05). In these three measurements, there was no statistical significance in the activities of enzymes in erythrocyte Cu-Zn SOD, CAT and GSH-Px in the placebo group. Before radiotherapy, plasma zinc levels were normal in 16 patients (59.2%) and were lower in 11 patients (40.8%) compared with laboratory levels. It would be worthwhile studying the effect of oral zinc sulphate supplements to improve the anti-oxidant enzyme activity in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.

Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis.

OBJECTIVE: Adenosine deaminase (ADA) is involved in purine metabolism and plays a significant role in the mechanisms of the immune system. The aim of this study was to investigate the correlation between the activity of total ADA (tADA) and isoenzymes ADA1 and ADA2 and clinical activity in patients with rheumatoid arthritis (RA). METHODS: The study comprised 37 patients with rheumatoid arthritis and 30 healthy controls. Total serum ADA activity was measured spectrophotometrically. The isoenzyme pattern of ADA was analyzed using erytro-9-(2-hydroxy-3-nonyl) adenine (EHNA). Disease activity was assessed using DAS criterion. RESULTS: The means of tADA, ADA1 and ADA2 levels were found to be 22.7 +/- 5.9, 3.9 +/- 2.0 and 18.8 +/- 4.9 IU/L in patients with RA, and 15.1 +/- 4.4, 4.1 +/- 1.2 and 11.0 +/- 3.7 IU/L in healthy control subjects. When compared to the healthy controls, serum tADA and ADA2 levels were significantly higher (p < 0.001) in patients with RA, but the decrease of ADA1 level was not statistically significant (p > 0.05). There was a strong correlation (r = 0.527, p < 0.001) between serum tADA level and disease activity by DAS (Pearson's rank correlation), and no correlation between tADA and CRP or ESR in the patient groups (p > 0.05). CONCLUSION: Serum tADA and ADA2 activity is closely associated with RA and these non-invasive investigations can be used as biochemical markers for inflammation. These may provide additional information regarding disease activity along with the traditional indices such as ESR and CRP.

Relationship of serum zinc levels to hand preference, skull length and serum gonadal hormone levels in right-handed young adults.

The association between serum zinc (Zn) level and the degree of hand preference was studied in right-handed young adults. Hand preference was scored by the Waterloo Handedness Questionnaire. Serum Zn level was determined by the flow injection analysis-atomic absorption technique. Zinc was found to be positively linearly and significantly correlated with the degree of right hand preference in the sample of males with familial sinistrality (FS+) and FS- females with right eye and right foot preference. There was a negative linear correlation between these variables in FS+ females. Skull length showed a significant negative linear correlation with zinc in FS+ males and females, but a positive linear correlation in FS- females. In FS- females, there was a significant positive linear correlation between serum gonadal hormone binding globulin (GBG) and serum Zn levels. In FS+ males, there was a significant negative linear correlation between serum GBG and Zn levels, and a significant positive linear correlation between serum free testosterone level and serum Zn level. It was suggested that zinc may influence the degree of the right hand preference by hormonal mechanisms according to genetically established brain organization.

Oxygen free radical scavengers and reperfusion injury in dog lung preserved in cold ischemia.

Oxygen-derived free radicals are now considered important contributors to tissue injury associated with ischemia and reperfusion. The purpose of this study was to determine the influence of oxygen free radical scavengers on reperfusion injury. The left lower lobes of 15 canine lungs were isolated, preserved, and then reperfused for 120 minutes. Three groups of lobes were studied: Group 1 (n = 5), without ischemia, group 2 (n = 5) four hours of cold ischemia in Euro-Collins solution, group 3 (n = 5) four hours cold ischemia+oxygen free radical scavenger glutathione (0.1 nmol/L) given at the moment of perfusion. Extravascular lung water (grams per gram of blood-free dry lobe weight) after reperfusion was 2.82 +/- 0.32, 5.06 +/- 0.45, 4.21 +/- 0.33 for groups 1 through 3 respectively (p less than 0.001 group 1 versus group 2, p less than 0.001 group 2 versus group 3). Lung tissue lipid peroxidation, measured as thiobarbituric acid reactive material was 125 +/- 11, 270 +/- 30, and 185 +/- 17 nmol/g dry lobe weight for groups 1, 2 and 3 respectively (p less than 0.05 group 2 versus 1 and group 3 versus group 2). The data suggest that oxygen free radical scavengers attenuate reperfusion injury.

Kinetic parameters of serum and lung tissue angiotensin-converting enzyme in patients with lung cancer.

Angiotensin-converting enzyme activity and its kinetic parameters were determined in both serum and lung tissue samples obtained from 17 patients with lung cancer and 21 control subjects, regardless of ethical base. The specific activities for cancerous and normal lung tissues were 67.2 +/- 27.3 (mean +/- SD) U/g protein and 28.5 +/- 5.4 U/g protein, respectively (P less than 0.001). Serum enzyme activity, on the other hand, was found to be higher in controls (198 +/- 42 U/L) than in patients (237 +/- 68 U/L) (P less than 0.01). The effects of chloride and zinc ions, pH and temperature on the enzyme activity were investigated as kinetic parameters in both serum and tissue samples.

Serum zinc and angiotensin-converting enzyme levels in patients with lung cancer.

Forty-two patients with lung cancer and 72 healthy subjects were studied in order to determine a possible relationship between serum zinc and angiotensin-converting enzyme (ACE), a peptidyl dipeptide hydrolase. Serum zinc levels were 105 +/- 21 micrograms/dl in control subjects and 50 +/- 19 micrograms/dl in patients, and angiotensin-converting enzyme activity was 296 +/- 28 U/l in the former and 240 +/- 55 U/l in the latter using hippurylglycylglycine as a substrate. The findings obtained show that the decreased levels of angiotensin-converting enzyme may be related to decreased serum zinc levels and that the primary defect may be the zinc deficiency in these patients.

Glycosylation of nail in diabetics: possible marker of long-term hyperglycemia.

Fingernail samples from 32 patients with diabetes mellitus and from 26 non-diabetics were analyzed in order to determine the protein glycosylation rate in nail. Nail glycosylation was assayed by the thiobarbituric acid reaction. Blood was taken from both diabetics and non-diabetics at the same time for measurement of hemoglobin glycosylation. In non-diabetics, the protein glycosylation in nail and glycosylated hemoglobin were found to be 8.35 +/- 2.7 nmol fructosamine/mg nail and 2.24 +/- 0.45 mumol fructosamine/g hemoglobin, respectively. In diabetics, however, there was an extremely high glycosylation in both nail protein and hemoglobin: 16.0 +/- 7.35 nmol fructosamine/mg nail and 5.17 +/- 1.17 mumol fructosamine/g hemoglobin (p less than 0.001 for both). A significant correlation was found between nail glycosylation and glycosylated hemoglobin in diabetics (r = 0.923, p less than 0.001). Also, there was a correlation between diabetic fasting blood glucose and protein glycosylation in nail (r = 0.947, p less than 0.001). Our findings show that it might be useful in the investigation of microvascular complications of diabetes mellitus to evaluate the possibility of nail glycosylation providing a stable long-term measure of tissue glycosylation.